AYA STEPS RCT: AYA Self-Management Via Texting, Education & Plans for Survivors
NCT03363711 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 25
Last updated 2026-01-08
Summary
The proposed project will leverage two programs of research at UPenn and CHOP that are delivering technology-based interventions to adolescent and young adult (AYA) cancer survivors.
In the proposed study, all AYA survivors will receive a care plan via a tool (Smart-ALACC). They will then be randomized to receive (or not) a mobile health application (AYA STEPS) that will provide tailored messages to enhance uptake of their care plan.
Conditions
- Adolescent and Young Adult (AYA) Cancer Survivors
Interventions
- OTHER
-
AYA STEPS
a mobile health application
Sponsors & Collaborators
-
Abramson Cancer Center at Penn Medicine
lead OTHER
Principal Investigators
-
Christine Hill-Kayser, MD · Abramson Cancer Center at Penn Medicine
Eligibility
- Min Age
- 15 Years
- Max Age
- 29 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-01
- Primary Completion
- 2019-12-01
- Completion
- 2026-12-31
Countries
- United States
Study Locations
More Related Trials
-
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
NCT04071236 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
Addressing Health Literacy With a Tailored Survivorship Care Plan
NCT06674863 ·Status: RECRUITING ·Phase: NA
-
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
NCT00638690 ·Status: COMPLETED ·Phase: PHASE3
-
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
NCT04876651 ·Status: TERMINATED ·Phase: PHASE3
-
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
NCT00003516 ·Status: TERMINATED ·Phase: PHASE2
-
Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers
NCT00223171 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
NCT00771017 ·Status: WITHDRAWN ·Phase: PHASE2
-
Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation
NCT00186420 ·Status: COMPLETED ·Phase: PHASE2
-
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
NCT04677855 ·Status: TERMINATED ·Phase: PHASE1
-
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
NCT03230734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
NCT00003517 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
NCT04100018 ·Status: COMPLETED ·Phase: PHASE3
-
Study of AZD0754 in Participants With Metastatic Prostate Cancer
NCT06267729 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
NCT06064149 ·Status: RECRUITING ·Phase: NA
-
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
NCT02478125 ·Status: TERMINATED ·Phase: PHASE1
-
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT02325557 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate
NCT01255891 ·Status: COMPLETED ·Phase: PHASE2
-
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
NCT03545165 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
NCT00459654 ·Status: COMPLETED ·Phase: PHASE2
-
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
NCT03770455 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04886986 ·Status: RECRUITING ·Phase: PHASE1